# Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

> **NCT04439929** · PHASE1 · COMPLETED · sponsor: **Turgut İlaçları A.Ş.** · enrollment: 168 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **BIOLOGICAL:** TUR01
- **BIOLOGICAL:** Adalimumab-EU

## Key facts

- **NCT ID:** NCT04439929
- **Lead sponsor:** Turgut İlaçları A.Ş.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-17
- **Primary completion:** 2020-01-16
- **Final completion:** 2020-01-16
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2020-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439929, "Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04439929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*